UC BON.CAP.CERT. 03/25 SNW/ DE000UG1FZV7 /
10/01/2025 17:46:21 | Chg.-0.310 | Bid17:52:29 | Ask17:52:29 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
110.560EUR | -0.28% | 110.750 Bid Size: 1,000 |
110.820 Ask Size: 1,000 |
SANOFI SA INHABER ... | - - | 28/03/2025 | Call |
GlobeNewswire
02/09/2024
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to ...
GlobeNewswire
26/08/2024
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...
GlobeNewswire
14/08/2024
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
GlobeNewswire
13/08/2024
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
12/08/2024
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter ...
GlobeNewswire
08/08/2024
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free sur...
GlobeNewswire
07/08/2024
Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire
06/08/2024
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D ...
GlobeNewswire
01/08/2024
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
31/07/2024
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2...
GlobeNewswire
25/07/2024
Press Release: Online availability of Sanofi’s half-year financial report for 2024
GlobeNewswire
25/07/2024
Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded